费用管控合理，多品种拉动增长

Investment Rating - The report maintains a "Buy" rating for the company [6] Core Insights - The company reported a revenue of 2.456 billion yuan in 2023, a year-on-year increase of 3.35%, and a net profit attributable to shareholders of 348 million yuan, up 139.33% year-on-year [6] - In Q1 2024, the company achieved a revenue of 736 million yuan, representing a year-on-year growth of 38.40%, and a net profit of 98 million yuan, up 90.95% year-on-year [6] - The revenue structure has diversified, with management and R&D expenses decreasing significantly, leading to improved profitability [6] - The company is advancing its R&D pipeline, with significant projects progressing through clinical trials, including the FDA acceptance of a key treatment application [6] - The company is expected to return to a rapid growth trajectory, driven by new product launches and the inclusion of several products in the national medical insurance directory [6] Financial Summary - Total revenue for 2023 was 2.456 billion yuan, with a projected revenue of 3.137 billion yuan for 2024, reflecting a growth rate of 27.7% [7] - The net profit for 2023 was 348 million yuan, with an expected net profit of 426 million yuan for 2024, indicating a growth rate of 22.5% [7] - The company’s gross margin is projected to remain stable, with a slight increase from 83.5% in 2023 to 84.5% by 2026 [7] - The price-to-earnings (PE) ratio is expected to decrease from 43 in 2023 to 20 by 2026, indicating a potential increase in valuation [7]